Cell Metabolism-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2243607, encodeId=d762224360eca, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：2月24 提交 2月27同行评审 4月17主要修订 9月12修订后提交 10月12预接受 12月17正式接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000001788822144, createdTime=Thu Dec 19 23:15:29 CST 2024, time=2024-12-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2243590, encodeId=b8a9224359081, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：感觉在李杰青的带领下，国人已经攻克了该杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Thu Dec 19 22:27:01 CST 2024, time=2024-12-19, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2243225, encodeId=5536224322532, content=with editor 13天了，估计没戏。CM编辑的处理流程是先编辑分配稿件，然后开会统一讨论，在下周二统一发出拒稿信（样本比较少，只有5，但都在周二），如果周四周五的稿件下周二来不及的会到下下周二才会拒掉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0ee5612681, createdName=ms2000001542264371, createdTime=Wed Dec 18 09:06:34 CST 2024, time=2024-12-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2205121, encodeId=4c3e22051219c, content=偏重的研究方向：代谢 经验分享：with editor 10天了，躺平等拒中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Thu May 16 23:18:49 CST 2024, time=2024-05-16, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2232999, encodeId=fedc223299932, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤代谢 经验分享：我只是想问一下MedSci网站是不是没人维护了，杂志收录的中国文章从2022起就没有更新了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e3c94025, createdName=sdjjd, createdTime=Fri Oct 25 00:43:50 CST 2024, time=2024-10-25, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=1015354, encodeId=20f21015354b3, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：非常奇怪，近两年武汉大学又连续发了好几篇，有点像当年nature medicine的套路。美国院士都少有能到这个水平的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=767, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Tue Sep 07 13:45:38 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197044, encodeId=72a5219e044e7, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;代谢 经验分享：5.24, 2023 submit 5.27, 2023 send out for peer review 7.18, 2023 major revision（invited） 12.20, 2023 revision submit 1.25, 2024 Pre-accept 3.28,2024 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Fri Apr 05 15:47:02 CST 2024, time=2024-04-05, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2186863, encodeId=70842186863e8, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：还在pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Sun Feb 11 00:46:55 CST 2024, time=2024-02-11, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2184158, encodeId=3f6421841585b, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：免疫;肿瘤;代谢 经验分享：5.24, 2023 submit 5.27, 2023 send out for peer review 7.18, 2023 major revision（invited） 12.20, 2023 revision submit 1.25, 2024 Pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Fri Jan 26 19:28:55 CST 2024, time=2024-01-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2164490, encodeId=fed421644909d, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：很难接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=404e5496225, createdName=Zhangbin861109, createdTime=Tue Oct 24 00:04:48 CST 2023, time=2023-10-24, status=1, ipAttribution=山东省)]

2024-12-19 ms3000001788822144 来自上海

审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向：肿瘤
经验分享：2月24 提交
2月27同行评审
4月17主要修订
9月12修订后提交
10月12预接受
12月17正式接

3 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2243607, encodeId=d762224360eca, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：2月24 提交 2月27同行评审 4月17主要修订 9月12修订后提交 10月12预接受 12月17正式接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000001788822144, createdTime=Thu Dec 19 23:15:29 CST 2024, time=2024-12-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2243590, encodeId=b8a9224359081, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：感觉在李杰青的带领下，国人已经攻克了该杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Thu Dec 19 22:27:01 CST 2024, time=2024-12-19, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2243225, encodeId=5536224322532, content=with editor 13天了，估计没戏。CM编辑的处理流程是先编辑分配稿件，然后开会统一讨论，在下周二统一发出拒稿信（样本比较少，只有5，但都在周二），如果周四周五的稿件下周二来不及的会到下下周二才会拒掉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0ee5612681, createdName=ms2000001542264371, createdTime=Wed Dec 18 09:06:34 CST 2024, time=2024-12-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2205121, encodeId=4c3e22051219c, content=偏重的研究方向：代谢 经验分享：with editor 10天了，躺平等拒中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Thu May 16 23:18:49 CST 2024, time=2024-05-16, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2232999, encodeId=fedc223299932, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤代谢 经验分享：我只是想问一下MedSci网站是不是没人维护了，杂志收录的中国文章从2022起就没有更新了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e3c94025, createdName=sdjjd, createdTime=Fri Oct 25 00:43:50 CST 2024, time=2024-10-25, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=1015354, encodeId=20f21015354b3, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：非常奇怪，近两年武汉大学又连续发了好几篇，有点像当年nature medicine的套路。美国院士都少有能到这个水平的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=767, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Tue Sep 07 13:45:38 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197044, encodeId=72a5219e044e7, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;代谢 经验分享：5.24, 2023 submit 5.27, 2023 send out for peer review 7.18, 2023 major revision（invited） 12.20, 2023 revision submit 1.25, 2024 Pre-accept 3.28,2024 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Fri Apr 05 15:47:02 CST 2024, time=2024-04-05, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2186863, encodeId=70842186863e8, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：还在pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Sun Feb 11 00:46:55 CST 2024, time=2024-02-11, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2184158, encodeId=3f6421841585b, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：免疫;肿瘤;代谢 经验分享：5.24, 2023 submit 5.27, 2023 send out for peer review 7.18, 2023 major revision（invited） 12.20, 2023 revision submit 1.25, 2024 Pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Fri Jan 26 19:28:55 CST 2024, time=2024-01-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2164490, encodeId=fed421644909d, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：很难接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=404e5496225, createdName=Zhangbin861109, createdTime=Tue Oct 24 00:04:48 CST 2023, time=2023-10-24, status=1, ipAttribution=山东省)]

2024-12-19 1811e984f8m 来自安徽省

审稿速度:2.0 | 投稿命中率:25.0
经验分享：感觉在李杰青的带领下，国人已经攻克了该杂志。

3 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2243607, encodeId=d762224360eca, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：2月24 提交 2月27同行评审 4月17主要修订 9月12修订后提交 10月12预接受 12月17正式接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000001788822144, createdTime=Thu Dec 19 23:15:29 CST 2024, time=2024-12-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2243590, encodeId=b8a9224359081, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：感觉在李杰青的带领下，国人已经攻克了该杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Thu Dec 19 22:27:01 CST 2024, time=2024-12-19, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2243225, encodeId=5536224322532, content=with editor 13天了，估计没戏。CM编辑的处理流程是先编辑分配稿件，然后开会统一讨论，在下周二统一发出拒稿信（样本比较少，只有5，但都在周二），如果周四周五的稿件下周二来不及的会到下下周二才会拒掉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0ee5612681, createdName=ms2000001542264371, createdTime=Wed Dec 18 09:06:34 CST 2024, time=2024-12-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2205121, encodeId=4c3e22051219c, content=偏重的研究方向：代谢 经验分享：with editor 10天了，躺平等拒中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Thu May 16 23:18:49 CST 2024, time=2024-05-16, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2232999, encodeId=fedc223299932, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤代谢 经验分享：我只是想问一下MedSci网站是不是没人维护了，杂志收录的中国文章从2022起就没有更新了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e3c94025, createdName=sdjjd, createdTime=Fri Oct 25 00:43:50 CST 2024, time=2024-10-25, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=1015354, encodeId=20f21015354b3, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：非常奇怪，近两年武汉大学又连续发了好几篇，有点像当年nature medicine的套路。美国院士都少有能到这个水平的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=767, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Tue Sep 07 13:45:38 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197044, encodeId=72a5219e044e7, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;代谢 经验分享：5.24, 2023 submit 5.27, 2023 send out for peer review 7.18, 2023 major revision（invited） 12.20, 2023 revision submit 1.25, 2024 Pre-accept 3.28,2024 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Fri Apr 05 15:47:02 CST 2024, time=2024-04-05, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2186863, encodeId=70842186863e8, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：还在pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Sun Feb 11 00:46:55 CST 2024, time=2024-02-11, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2184158, encodeId=3f6421841585b, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：免疫;肿瘤;代谢 经验分享：5.24, 2023 submit 5.27, 2023 send out for peer review 7.18, 2023 major revision（invited） 12.20, 2023 revision submit 1.25, 2024 Pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Fri Jan 26 19:28:55 CST 2024, time=2024-01-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2164490, encodeId=fed421644909d, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：很难接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=404e5496225, createdName=Zhangbin861109, createdTime=Tue Oct 24 00:04:48 CST 2023, time=2023-10-24, status=1, ipAttribution=山东省)]

2024-12-18 ms2000001542264371 来自浙江省

with editor 13天了，估计没戏。CM编辑的处理流程是先编辑分配稿件，然后开会统一讨论，在下周二统一发出拒稿信（样本比较少，只有5，但都在周二），如果周四周五的稿件下周二来不及的会到下下周二才会拒掉

0 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2243607, encodeId=d762224360eca, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：2月24 提交 2月27同行评审 4月17主要修订 9月12修订后提交 10月12预接受 12月17正式接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000001788822144, createdTime=Thu Dec 19 23:15:29 CST 2024, time=2024-12-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2243590, encodeId=b8a9224359081, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：感觉在李杰青的带领下，国人已经攻克了该杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Thu Dec 19 22:27:01 CST 2024, time=2024-12-19, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2243225, encodeId=5536224322532, content=with editor 13天了，估计没戏。CM编辑的处理流程是先编辑分配稿件，然后开会统一讨论，在下周二统一发出拒稿信（样本比较少，只有5，但都在周二），如果周四周五的稿件下周二来不及的会到下下周二才会拒掉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0ee5612681, createdName=ms2000001542264371, createdTime=Wed Dec 18 09:06:34 CST 2024, time=2024-12-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2205121, encodeId=4c3e22051219c, content=偏重的研究方向：代谢 经验分享：with editor 10天了，躺平等拒中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Thu May 16 23:18:49 CST 2024, time=2024-05-16, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2232999, encodeId=fedc223299932, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤代谢 经验分享：我只是想问一下MedSci网站是不是没人维护了，杂志收录的中国文章从2022起就没有更新了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e3c94025, createdName=sdjjd, createdTime=Fri Oct 25 00:43:50 CST 2024, time=2024-10-25, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=1015354, encodeId=20f21015354b3, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：非常奇怪，近两年武汉大学又连续发了好几篇，有点像当年nature medicine的套路。美国院士都少有能到这个水平的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=767, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Tue Sep 07 13:45:38 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197044, encodeId=72a5219e044e7, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;代谢 经验分享：5.24, 2023 submit 5.27, 2023 send out for peer review 7.18, 2023 major revision（invited） 12.20, 2023 revision submit 1.25, 2024 Pre-accept 3.28,2024 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Fri Apr 05 15:47:02 CST 2024, time=2024-04-05, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2186863, encodeId=70842186863e8, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：还在pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Sun Feb 11 00:46:55 CST 2024, time=2024-02-11, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2184158, encodeId=3f6421841585b, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：免疫;肿瘤;代谢 经验分享：5.24, 2023 submit 5.27, 2023 send out for peer review 7.18, 2023 major revision（invited） 12.20, 2023 revision submit 1.25, 2024 Pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Fri Jan 26 19:28:55 CST 2024, time=2024-01-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2164490, encodeId=fed421644909d, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：很难接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=404e5496225, createdName=Zhangbin861109, createdTime=Tue Oct 24 00:04:48 CST 2023, time=2023-10-24, status=1, ipAttribution=山东省)]

2024-05-16 Charlo 来自安徽省

偏重的研究方向：代谢
经验分享：with editor 10天了，躺平等拒中。

102 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2243607, encodeId=d762224360eca, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：2月24 提交 2月27同行评审 4月17主要修订 9月12修订后提交 10月12预接受 12月17正式接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000001788822144, createdTime=Thu Dec 19 23:15:29 CST 2024, time=2024-12-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2243590, encodeId=b8a9224359081, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：感觉在李杰青的带领下，国人已经攻克了该杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Thu Dec 19 22:27:01 CST 2024, time=2024-12-19, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2243225, encodeId=5536224322532, content=with editor 13天了，估计没戏。CM编辑的处理流程是先编辑分配稿件，然后开会统一讨论，在下周二统一发出拒稿信（样本比较少，只有5，但都在周二），如果周四周五的稿件下周二来不及的会到下下周二才会拒掉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0ee5612681, createdName=ms2000001542264371, createdTime=Wed Dec 18 09:06:34 CST 2024, time=2024-12-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2205121, encodeId=4c3e22051219c, content=偏重的研究方向：代谢 经验分享：with editor 10天了，躺平等拒中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Thu May 16 23:18:49 CST 2024, time=2024-05-16, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2232999, encodeId=fedc223299932, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤代谢 经验分享：我只是想问一下MedSci网站是不是没人维护了，杂志收录的中国文章从2022起就没有更新了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e3c94025, createdName=sdjjd, createdTime=Fri Oct 25 00:43:50 CST 2024, time=2024-10-25, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=1015354, encodeId=20f21015354b3, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：非常奇怪，近两年武汉大学又连续发了好几篇，有点像当年nature medicine的套路。美国院士都少有能到这个水平的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=767, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Tue Sep 07 13:45:38 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197044, encodeId=72a5219e044e7, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;代谢 经验分享：5.24, 2023 submit 5.27, 2023 send out for peer review 7.18, 2023 major revision（invited） 12.20, 2023 revision submit 1.25, 2024 Pre-accept 3.28,2024 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Fri Apr 05 15:47:02 CST 2024, time=2024-04-05, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2186863, encodeId=70842186863e8, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：还在pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Sun Feb 11 00:46:55 CST 2024, time=2024-02-11, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2184158, encodeId=3f6421841585b, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：免疫;肿瘤;代谢 经验分享：5.24, 2023 submit 5.27, 2023 send out for peer review 7.18, 2023 major revision（invited） 12.20, 2023 revision submit 1.25, 2024 Pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Fri Jan 26 19:28:55 CST 2024, time=2024-01-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2164490, encodeId=fed421644909d, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：很难接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=404e5496225, createdName=Zhangbin861109, createdTime=Tue Oct 24 00:04:48 CST 2023, time=2023-10-24, status=1, ipAttribution=山东省)]

2024-10-25 sdjjd 来自美国

审稿速度:6.0 | 投稿命中率:25.0
偏重的研究方向：肿瘤代谢
经验分享：我只是想问一下MedSci网站是不是没人维护了，杂志收录的中国文章从2022起就没有更新了。

20 0

[GetPortalCommentsPageByObjectIdResponse(id=2243607, encodeId=d762224360eca, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：2月24 提交 2月27同行评审 4月17主要修订 9月12修订后提交 10月12预接受 12月17正式接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000001788822144, createdTime=Thu Dec 19 23:15:29 CST 2024, time=2024-12-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2243590, encodeId=b8a9224359081, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：感觉在李杰青的带领下，国人已经攻克了该杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Thu Dec 19 22:27:01 CST 2024, time=2024-12-19, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2243225, encodeId=5536224322532, content=with editor 13天了，估计没戏。CM编辑的处理流程是先编辑分配稿件，然后开会统一讨论，在下周二统一发出拒稿信（样本比较少，只有5，但都在周二），如果周四周五的稿件下周二来不及的会到下下周二才会拒掉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0ee5612681, createdName=ms2000001542264371, createdTime=Wed Dec 18 09:06:34 CST 2024, time=2024-12-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2205121, encodeId=4c3e22051219c, content=偏重的研究方向：代谢 经验分享：with editor 10天了，躺平等拒中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Thu May 16 23:18:49 CST 2024, time=2024-05-16, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2232999, encodeId=fedc223299932, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤代谢 经验分享：我只是想问一下MedSci网站是不是没人维护了，杂志收录的中国文章从2022起就没有更新了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e3c94025, createdName=sdjjd, createdTime=Fri Oct 25 00:43:50 CST 2024, time=2024-10-25, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=1015354, encodeId=20f21015354b3, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：非常奇怪，近两年武汉大学又连续发了好几篇，有点像当年nature medicine的套路。美国院士都少有能到这个水平的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=767, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Tue Sep 07 13:45:38 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197044, encodeId=72a5219e044e7, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;代谢 经验分享：5.24, 2023 submit 5.27, 2023 send out for peer review 7.18, 2023 major revision（invited） 12.20, 2023 revision submit 1.25, 2024 Pre-accept 3.28,2024 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Fri Apr 05 15:47:02 CST 2024, time=2024-04-05, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2186863, encodeId=70842186863e8, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：还在pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Sun Feb 11 00:46:55 CST 2024, time=2024-02-11, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2184158, encodeId=3f6421841585b, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：免疫;肿瘤;代谢 经验分享：5.24, 2023 submit 5.27, 2023 send out for peer review 7.18, 2023 major revision（invited） 12.20, 2023 revision submit 1.25, 2024 Pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Fri Jan 26 19:28:55 CST 2024, time=2024-01-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2164490, encodeId=fed421644909d, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：很难接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=404e5496225, createdName=Zhangbin861109, createdTime=Tue Oct 24 00:04:48 CST 2023, time=2023-10-24, status=1, ipAttribution=山东省)]

2021-09-07 张晓梅-Xiaomei Zhang

审稿速度:1.0 | 投稿命中率:5.0
经验分享：非常奇怪，近两年武汉大学又连续发了好几篇，有点像当年nature medicine的套路。美国院士都少有能到这个水平的

767 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2243607, encodeId=d762224360eca, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：2月24 提交 2月27同行评审 4月17主要修订 9月12修订后提交 10月12预接受 12月17正式接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000001788822144, createdTime=Thu Dec 19 23:15:29 CST 2024, time=2024-12-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2243590, encodeId=b8a9224359081, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：感觉在李杰青的带领下，国人已经攻克了该杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Thu Dec 19 22:27:01 CST 2024, time=2024-12-19, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2243225, encodeId=5536224322532, content=with editor 13天了，估计没戏。CM编辑的处理流程是先编辑分配稿件，然后开会统一讨论，在下周二统一发出拒稿信（样本比较少，只有5，但都在周二），如果周四周五的稿件下周二来不及的会到下下周二才会拒掉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0ee5612681, createdName=ms2000001542264371, createdTime=Wed Dec 18 09:06:34 CST 2024, time=2024-12-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2205121, encodeId=4c3e22051219c, content=偏重的研究方向：代谢 经验分享：with editor 10天了，躺平等拒中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Thu May 16 23:18:49 CST 2024, time=2024-05-16, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2232999, encodeId=fedc223299932, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤代谢 经验分享：我只是想问一下MedSci网站是不是没人维护了，杂志收录的中国文章从2022起就没有更新了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e3c94025, createdName=sdjjd, createdTime=Fri Oct 25 00:43:50 CST 2024, time=2024-10-25, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=1015354, encodeId=20f21015354b3, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：非常奇怪，近两年武汉大学又连续发了好几篇，有点像当年nature medicine的套路。美国院士都少有能到这个水平的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=767, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Tue Sep 07 13:45:38 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197044, encodeId=72a5219e044e7, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;代谢 经验分享：5.24, 2023 submit 5.27, 2023 send out for peer review 7.18, 2023 major revision（invited） 12.20, 2023 revision submit 1.25, 2024 Pre-accept 3.28,2024 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Fri Apr 05 15:47:02 CST 2024, time=2024-04-05, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2186863, encodeId=70842186863e8, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：还在pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Sun Feb 11 00:46:55 CST 2024, time=2024-02-11, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2184158, encodeId=3f6421841585b, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：免疫;肿瘤;代谢 经验分享：5.24, 2023 submit 5.27, 2023 send out for peer review 7.18, 2023 major revision（invited） 12.20, 2023 revision submit 1.25, 2024 Pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Fri Jan 26 19:28:55 CST 2024, time=2024-01-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2164490, encodeId=fed421644909d, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：很难接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=404e5496225, createdName=Zhangbin861109, createdTime=Tue Oct 24 00:04:48 CST 2023, time=2023-10-24, status=1, ipAttribution=山东省)]

2024-04-05 1224989703 来自重庆

审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向：肿瘤;代谢
经验分享：5.24, 2023 submit

5.27, 2023 send out for peer review

7.18, 2023 major revision（invited）

12.20, 2023 revision submit

1.25, 2024 Pre-accept

3.28,2024 Accept

113 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2243607, encodeId=d762224360eca, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：2月24 提交 2月27同行评审 4月17主要修订 9月12修订后提交 10月12预接受 12月17正式接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000001788822144, createdTime=Thu Dec 19 23:15:29 CST 2024, time=2024-12-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2243590, encodeId=b8a9224359081, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：感觉在李杰青的带领下，国人已经攻克了该杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Thu Dec 19 22:27:01 CST 2024, time=2024-12-19, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2243225, encodeId=5536224322532, content=with editor 13天了，估计没戏。CM编辑的处理流程是先编辑分配稿件，然后开会统一讨论，在下周二统一发出拒稿信（样本比较少，只有5，但都在周二），如果周四周五的稿件下周二来不及的会到下下周二才会拒掉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0ee5612681, createdName=ms2000001542264371, createdTime=Wed Dec 18 09:06:34 CST 2024, time=2024-12-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2205121, encodeId=4c3e22051219c, content=偏重的研究方向：代谢 经验分享：with editor 10天了，躺平等拒中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Thu May 16 23:18:49 CST 2024, time=2024-05-16, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2232999, encodeId=fedc223299932, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤代谢 经验分享：我只是想问一下MedSci网站是不是没人维护了，杂志收录的中国文章从2022起就没有更新了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e3c94025, createdName=sdjjd, createdTime=Fri Oct 25 00:43:50 CST 2024, time=2024-10-25, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=1015354, encodeId=20f21015354b3, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：非常奇怪，近两年武汉大学又连续发了好几篇，有点像当年nature medicine的套路。美国院士都少有能到这个水平的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=767, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Tue Sep 07 13:45:38 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197044, encodeId=72a5219e044e7, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;代谢 经验分享：5.24, 2023 submit 5.27, 2023 send out for peer review 7.18, 2023 major revision（invited） 12.20, 2023 revision submit 1.25, 2024 Pre-accept 3.28,2024 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Fri Apr 05 15:47:02 CST 2024, time=2024-04-05, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2186863, encodeId=70842186863e8, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：还在pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Sun Feb 11 00:46:55 CST 2024, time=2024-02-11, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2184158, encodeId=3f6421841585b, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：免疫;肿瘤;代谢 经验分享：5.24, 2023 submit 5.27, 2023 send out for peer review 7.18, 2023 major revision（invited） 12.20, 2023 revision submit 1.25, 2024 Pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Fri Jan 26 19:28:55 CST 2024, time=2024-01-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2164490, encodeId=fed421644909d, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：很难接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=404e5496225, createdName=Zhangbin861109, createdTime=Tue Oct 24 00:04:48 CST 2023, time=2023-10-24, status=1, ipAttribution=山东省)]

2024-02-11 1224989703 来自重庆

审稿速度:2.0 | 投稿命中率:25.0
经验分享：还在pre-accept

171 0

[GetPortalCommentsPageByObjectIdResponse(id=2243607, encodeId=d762224360eca, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：2月24 提交 2月27同行评审 4月17主要修订 9月12修订后提交 10月12预接受 12月17正式接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000001788822144, createdTime=Thu Dec 19 23:15:29 CST 2024, time=2024-12-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2243590, encodeId=b8a9224359081, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：感觉在李杰青的带领下，国人已经攻克了该杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Thu Dec 19 22:27:01 CST 2024, time=2024-12-19, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2243225, encodeId=5536224322532, content=with editor 13天了，估计没戏。CM编辑的处理流程是先编辑分配稿件，然后开会统一讨论，在下周二统一发出拒稿信（样本比较少，只有5，但都在周二），如果周四周五的稿件下周二来不及的会到下下周二才会拒掉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0ee5612681, createdName=ms2000001542264371, createdTime=Wed Dec 18 09:06:34 CST 2024, time=2024-12-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2205121, encodeId=4c3e22051219c, content=偏重的研究方向：代谢 经验分享：with editor 10天了，躺平等拒中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Thu May 16 23:18:49 CST 2024, time=2024-05-16, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2232999, encodeId=fedc223299932, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤代谢 经验分享：我只是想问一下MedSci网站是不是没人维护了，杂志收录的中国文章从2022起就没有更新了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e3c94025, createdName=sdjjd, createdTime=Fri Oct 25 00:43:50 CST 2024, time=2024-10-25, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=1015354, encodeId=20f21015354b3, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：非常奇怪，近两年武汉大学又连续发了好几篇，有点像当年nature medicine的套路。美国院士都少有能到这个水平的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=767, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Tue Sep 07 13:45:38 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197044, encodeId=72a5219e044e7, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;代谢 经验分享：5.24, 2023 submit 5.27, 2023 send out for peer review 7.18, 2023 major revision（invited） 12.20, 2023 revision submit 1.25, 2024 Pre-accept 3.28,2024 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Fri Apr 05 15:47:02 CST 2024, time=2024-04-05, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2186863, encodeId=70842186863e8, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：还在pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Sun Feb 11 00:46:55 CST 2024, time=2024-02-11, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2184158, encodeId=3f6421841585b, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：免疫;肿瘤;代谢 经验分享：5.24, 2023 submit 5.27, 2023 send out for peer review 7.18, 2023 major revision（invited） 12.20, 2023 revision submit 1.25, 2024 Pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Fri Jan 26 19:28:55 CST 2024, time=2024-01-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2164490, encodeId=fed421644909d, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：很难接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=404e5496225, createdName=Zhangbin861109, createdTime=Tue Oct 24 00:04:48 CST 2023, time=2023-10-24, status=1, ipAttribution=山东省)]

2024-01-26 1224989703 来自广东省

审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向：免疫;肿瘤;代谢
经验分享：5.24, 2023 submit

5.27, 2023 send out for peer review

7.18, 2023 major revision（invited）

12.20, 2023 revision submit

1.25, 2024 Pre-accept

182 0

[GetPortalCommentsPageByObjectIdResponse(id=2243607, encodeId=d762224360eca, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：2月24 提交 2月27同行评审 4月17主要修订 9月12修订后提交 10月12预接受 12月17正式接, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000001788822144, createdTime=Thu Dec 19 23:15:29 CST 2024, time=2024-12-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2243590, encodeId=b8a9224359081, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：感觉在李杰青的带领下，国人已经攻克了该杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Thu Dec 19 22:27:01 CST 2024, time=2024-12-19, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2243225, encodeId=5536224322532, content=with editor 13天了，估计没戏。CM编辑的处理流程是先编辑分配稿件，然后开会统一讨论，在下周二统一发出拒稿信（样本比较少，只有5，但都在周二），如果周四周五的稿件下周二来不及的会到下下周二才会拒掉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0ee5612681, createdName=ms2000001542264371, createdTime=Wed Dec 18 09:06:34 CST 2024, time=2024-12-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2205121, encodeId=4c3e22051219c, content=偏重的研究方向：代谢 经验分享：with editor 10天了，躺平等拒中。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Thu May 16 23:18:49 CST 2024, time=2024-05-16, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2232999, encodeId=fedc223299932, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤代谢 经验分享：我只是想问一下MedSci网站是不是没人维护了，杂志收录的中国文章从2022起就没有更新了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e3c94025, createdName=sdjjd, createdTime=Fri Oct 25 00:43:50 CST 2024, time=2024-10-25, status=1, ipAttribution=美国), GetPortalCommentsPageByObjectIdResponse(id=1015354, encodeId=20f21015354b3, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：非常奇怪，近两年武汉大学又连续发了好几篇，有点像当年nature medicine的套路。美国院士都少有能到这个水平的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=767, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Tue Sep 07 13:45:38 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197044, encodeId=72a5219e044e7, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;代谢 经验分享：5.24, 2023 submit 5.27, 2023 send out for peer review 7.18, 2023 major revision（invited） 12.20, 2023 revision submit 1.25, 2024 Pre-accept 3.28,2024 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Fri Apr 05 15:47:02 CST 2024, time=2024-04-05, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2186863, encodeId=70842186863e8, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：还在pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Sun Feb 11 00:46:55 CST 2024, time=2024-02-11, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2184158, encodeId=3f6421841585b, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：免疫;肿瘤;代谢 经验分享：5.24, 2023 submit 5.27, 2023 send out for peer review 7.18, 2023 major revision（invited） 12.20, 2023 revision submit 1.25, 2024 Pre-accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=11734857209, createdName=1224989703, createdTime=Fri Jan 26 19:28:55 CST 2024, time=2024-01-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2164490, encodeId=fed421644909d, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：很难接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=404e5496225, createdName=Zhangbin861109, createdTime=Tue Oct 24 00:04:48 CST 2023, time=2023-10-24, status=1, ipAttribution=山东省)]

2023-10-24 Zhangbin861109 来自山东省

审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向：肿瘤
经验分享：很难接收

171 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务